In context
Sermorelin is a growth-hormone-releasing hormone analogue. An original study compared GHRH(1–29) treatment regimens with growth hormone in children with growth-hormone deficiency of hypothalamic origin. [1]
At a glance
- Type
- Peptide / related clinical research
- Regulatory context
- The cited source describes research, not a determination of present marketing authorisation. Country, formulation and indication must be checked separately.
- Evidence
- A study in children with a defined deficiency does not establish anti-ageing benefit in adults. Historical clinical research is distinct from the status of a currently compounded product.
How to interpret this evidence
A study in children with a defined deficiency does not establish anti-ageing benefit in adults. Historical clinical research is distinct from the status of a currently compounded product. [1]
Safety and clinical context
The evidence described here does not establish safety for unsupervised use. Product identity, route, formulation, interactions and long-term effects cannot be inferred from a study category.
Evidence and authorisation depend on the product, formulation, indication and country. US labelling does not establish Thai authorisation. This guide is educational and is not a dosing or self-treatment protocol.
Primary sources
Read the underlying source and its limitations. A study citation does not by itself establish efficacy or approval.
- Growth response to growth hormone-releasing hormone(1-29)-NH2 compared with growth hormone. pubmed.ncbi.nlm.nih.gov